ES2653487T3 - Receptor de antígeno quimérico y métodos de uso del mismo - Google Patents
Receptor de antígeno quimérico y métodos de uso del mismo Download PDFInfo
- Publication number
- ES2653487T3 ES2653487T3 ES14751227T ES14751227T ES2653487T3 ES 2653487 T3 ES2653487 T3 ES 2653487T3 ES 14751227 T ES14751227 T ES 14751227T ES 14751227 T ES14751227 T ES 14751227T ES 2653487 T3 ES2653487 T3 ES 2653487T3
- Authority
- ES
- Spain
- Prior art keywords
- domain
- pair
- polypeptide
- specific binding
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 3
- 230000000139 costimulatory effect Effects 0.000 abstract 5
- 238000006471 dimerization reaction Methods 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 230000009870 specific binding Effects 0.000 abstract 4
- 230000004068 intracellular signaling Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000447 dimerizing effect Effects 0.000 abstract 1
- 239000000833 heterodimer Substances 0.000 abstract 1
- 239000000710 homodimer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Un receptor de antígeno quimérico (CAR) heterodimérico condicionalmente activo que comprende: a) un primer polipéptido que comprende: i) un primer miembro de un par de unión específica; ii) un primer dominio coestimulador; iii) un primer miembro de un par de dimerización; y iv) un dominio transmembrana interpuesto entre el primer miembro de un par de unión específica y el primer dominio coestimulador; y b) un segundo polipéptido que comprende: i) un dominio transmembrana; ii) un segundo dominio coestimulador; iii) un segundo miembro del par de dimerización; y iv) un dominio de señalización intracelular; o que comprende: a) un primer polipéptido que comprende: i) un primer miembro de un par de unión específica; ii) un dominio coestimulador; iii) un primer miembro de un par de dimerización; iv) un dominio transmembrana interpuesto entre el primer miembro de un par de unión específica y el dominio coestimulador; y b) un segundo polipéptido que comprende: i) un segundo miembro del par de dimerización; y ii) un dominio de señalización intracelular, en donde los miembros primero y segundo del par de dimerización forman un homodímero o un heterodímero en presencia de un agente dimerizador
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361765585P | 2013-02-15 | 2013-02-15 | |
PCT/US2014/016527 WO2014127261A1 (en) | 2013-02-15 | 2014-02-14 | Chimeric antigen receptor and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2653487T3 true ES2653487T3 (es) | 2018-02-07 |
Family
ID=51354582
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES19188398T Active ES2868247T3 (es) | 2013-02-15 | 2014-02-14 | Receptor de antígeno quimérico y métodos de uso del mismo |
ES17187293T Active ES2758227T3 (es) | 2013-02-15 | 2014-02-14 | Receptor de antígeno quimérico y métodos de uso del mismo |
ES14751227T Active ES2653487T3 (es) | 2013-02-15 | 2014-02-14 | Receptor de antígeno quimérico y métodos de uso del mismo |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES19188398T Active ES2868247T3 (es) | 2013-02-15 | 2014-02-14 | Receptor de antígeno quimérico y métodos de uso del mismo |
ES17187293T Active ES2758227T3 (es) | 2013-02-15 | 2014-02-14 | Receptor de antígeno quimérico y métodos de uso del mismo |
Country Status (22)
Country | Link |
---|---|
US (9) | US20150368342A1 (es) |
EP (5) | EP3881868B1 (es) |
JP (5) | JP6450690B2 (es) |
KR (5) | KR102132246B1 (es) |
CN (2) | CN110423282B (es) |
AU (5) | AU2014216130B2 (es) |
BR (1) | BR112015019640A2 (es) |
CA (1) | CA2901115A1 (es) |
CY (1) | CY1122386T1 (es) |
DK (2) | DK3300745T3 (es) |
ES (3) | ES2868247T3 (es) |
HK (2) | HK1218625A1 (es) |
HR (1) | HRP20192123T1 (es) |
HU (2) | HUE036250T2 (es) |
IL (3) | IL305629A (es) |
LT (2) | LT2956175T (es) |
MX (2) | MX369545B (es) |
NO (1) | NO2929995T3 (es) |
PL (3) | PL3300745T3 (es) |
PT (3) | PT3613439T (es) |
SI (2) | SI3300745T1 (es) |
WO (1) | WO2014127261A1 (es) |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3279315A3 (en) * | 2012-05-25 | 2018-02-28 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
CN110423282B (zh) | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
SG11201506974XA (en) | 2013-03-14 | 2015-10-29 | Bellicum Pharmaceuticals Inc | Methods for controlling t cell proliferation |
WO2014145252A2 (en) * | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CA2956667A1 (en) * | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
CA2925421C (en) | 2013-09-24 | 2023-08-29 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
RS60443B1 (sr) | 2013-12-17 | 2020-07-31 | Genentech Inc | Anti-cd3 antitela i postupci upotrebe |
EP3087101A4 (en) * | 2013-12-20 | 2017-12-06 | Novartis AG | Regulatable chimeric antigen receptor |
AU2015206040B2 (en) | 2014-01-14 | 2018-11-01 | Cellectis | Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish |
CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
EP3811970A1 (en) * | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
WO2015174928A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
EP3685842B1 (en) * | 2014-06-06 | 2022-08-31 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3660042B1 (en) | 2014-07-31 | 2023-01-11 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
CN107074975A (zh) * | 2014-08-28 | 2017-08-18 | 生物蛋白有限公司 | 用于修饰的t细胞的条件活性嵌合抗原受体 |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
WO2016054013A1 (en) * | 2014-10-03 | 2016-04-07 | Yale University | Innate immune system modification for anticancer therapy |
EP3204491A1 (en) * | 2014-10-07 | 2017-08-16 | Cellectis | Method for modulating car-induced immune cells activity |
EP3204777A1 (en) | 2014-10-08 | 2017-08-16 | Novartis AG | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
JP2017537622A (ja) * | 2014-12-02 | 2017-12-21 | ロジャー・ウィリアムズ・ホスピタル | がんを治療するための方法及び組成物 |
CN107206077B (zh) | 2014-12-05 | 2021-06-08 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
LT3227339T (lt) | 2014-12-05 | 2022-01-10 | Memorial Sloan-Kettering Cancer Center | Chimeriniai antigeno receptoriai, nukreipti į receptorių su prijungtu g baltymu ir jų naudojimo būdai |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
EP3608408A1 (en) * | 2014-12-15 | 2020-02-12 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
JP6718450B2 (ja) * | 2014-12-19 | 2020-07-08 | イーティーエッチ チューリッヒ | キメラ抗原受容体及びその使用方法 |
US20190054117A1 (en) * | 2014-12-19 | 2019-02-21 | Novartis Ag | Dimerization switches and uses thereof |
DK3237436T3 (da) | 2014-12-24 | 2019-08-12 | Aadigen Llc | Peptider og nanopartikler til intracellulær indgivelse af molekyler |
US10273300B2 (en) | 2014-12-29 | 2019-04-30 | The Trustees Of The University Of Pennsylvania | Methods of making chimeric antigen receptor-expressing cells |
GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
WO2016138491A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
US10195272B2 (en) | 2015-03-02 | 2019-02-05 | The Nemours Foundation | Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases |
GB201504840D0 (en) * | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
KR20170134525A (ko) * | 2015-04-02 | 2017-12-06 | 메모리얼 슬로안-케터링 캔서 센터 | Tnfrsf14 / hvem 단백질 및 이의 이용 방법 |
HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
EP3283113A4 (en) * | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
GB201507111D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
KR20180021137A (ko) | 2015-06-25 | 2018-02-28 | 아이셀 진 테라퓨틱스 엘엘씨 | 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법 |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
RU2724738C2 (ru) * | 2015-08-05 | 2020-06-25 | СеллабМЕД ИНК. | Химерный антигенный рецептор и т-клетки, в которых экспрессируется химерный антигенный рецептор |
EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
US11667691B2 (en) * | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
JP6894430B2 (ja) | 2015-08-24 | 2021-06-30 | セレクティスCellectis | 統合された制御機能を有するキメラ抗原受容体 |
EP3954772B1 (en) * | 2015-09-01 | 2023-10-25 | The Regents of The University of California | Modular polypeptide libraries and methods of making and using same |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
EP3569244A1 (en) | 2015-09-23 | 2019-11-20 | CytoImmune Therapeutics, LLC | Flt3 directed car cells for immunotherapy |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
EP3377523A4 (en) * | 2015-11-19 | 2019-06-19 | The Regents of The University of California | IMMUNITY CELL RECEIVERS REPRESSIBLE UNDER CONDITIONS AND METHODS OF USING THE SAME |
JP2018538277A (ja) * | 2015-11-23 | 2018-12-27 | トラスティーズ オブ ボストン ユニバーシティ | キメラ抗原受容体に関する方法および組成物 |
PE20181535A1 (es) | 2015-12-16 | 2018-09-26 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno |
EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
KR20180096788A (ko) * | 2016-01-08 | 2018-08-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 조건적 활성 이종이량체 폴리펩티드 및 이의 사용 방법 |
MY196175A (en) | 2016-01-11 | 2023-03-20 | Univ Leland Stanford Junior | Chimeric Proteins And Methods Of Regulating Gene Expression |
MY194127A (en) | 2016-01-11 | 2022-11-14 | Univ Leland Stanford Junior | Chimeric proteins and methods of immunotherapy |
CN105567640A (zh) * | 2016-01-27 | 2016-05-11 | 苏州佰通生物科技有限公司 | 一种嵌合抗原受体脂肪干细胞及其制备方法 |
GB201602563D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
GB201602571D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
US10871490B2 (en) | 2016-02-29 | 2020-12-22 | Multenyi Biotec, gmbH | Assay for detection of chimeric antigen receptor T cells |
AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
CA3018253A1 (en) | 2016-03-31 | 2017-10-05 | University Of Southern California | A highly sensitive and specific luciferase based reporter assay for antigen detection |
KR102591930B1 (ko) | 2016-04-01 | 2023-10-24 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
EA201892193A1 (ru) | 2016-04-01 | 2019-06-28 | Амген Инк. | Химерные рецепторы к flt3 и способы их применения |
UA123276C2 (uk) | 2016-04-01 | 2021-03-10 | Кайт Фарма, Інк. | Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення |
WO2017173256A1 (en) | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
EP3443002A4 (en) * | 2016-04-14 | 2019-12-04 | Bluebird Bio, Inc. | RECOVERY ANTIGEN RECEPTOR SYSTEMS |
EP4180519A1 (en) | 2016-04-15 | 2023-05-17 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses |
US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
US11384156B2 (en) | 2016-07-25 | 2022-07-12 | The Nemours Foundation | Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases |
JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 |
WO2018027197A1 (en) * | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
CN109789164B (zh) * | 2016-08-30 | 2023-04-28 | 亘喜生物科技(上海)有限公司 | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 |
US20180064758A1 (en) * | 2016-09-05 | 2018-03-08 | Ucl Business Plc | Chimeric antigen receptor |
CN107793483B (zh) * | 2016-09-06 | 2019-08-23 | 伍志强 | 嵌合抗原受体及其基因和重组表达载体、carmsln-nkt细胞及其制备方法和应用 |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
JP6698854B2 (ja) * | 2016-09-16 | 2020-05-27 | キッセイ薬品工業株式会社 | 遺伝子改変細胞及びその作製方法 |
JP6887492B6 (ja) * | 2016-10-04 | 2021-07-14 | プレシジョン バイオサイエンシズ,インク. | 遺伝子改変細胞で使用するための共刺激ドメイン |
MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
CA3041284A1 (en) * | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
CN107058315B (zh) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
WO2018111834A1 (en) * | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
WO2018112266A1 (en) | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
AU2018207300B2 (en) * | 2017-01-10 | 2023-08-24 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
CN107573419A (zh) * | 2017-01-24 | 2018-01-12 | 深圳市体内生物医药科技有限公司 | 一种增强t细胞抗肿瘤活性的核酸分子 |
EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
CN111386263A (zh) * | 2017-02-08 | 2020-07-07 | 达纳-法伯癌症研究所有限公司 | 调节嵌合抗原受体 |
CN110582288A (zh) | 2017-02-28 | 2019-12-17 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
TW201837175A (zh) | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
JP7256749B2 (ja) | 2017-03-27 | 2023-04-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における切断されたnkg2dキメラ受容体及びその使用 |
MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
JOP20180027A1 (ar) | 2017-03-28 | 2019-01-30 | Cell Design Labs Inc | بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
CN110582280B (zh) * | 2017-03-31 | 2024-03-19 | 小利兰·斯坦福大学托管委员会 | 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法 |
EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
CA3061676A1 (en) * | 2017-05-12 | 2018-11-15 | Cellectis | Protease based switch chimeric antigen receptors for safer cell immunotherapy |
US20200188434A1 (en) * | 2017-05-15 | 2020-06-18 | Autolus Limited | A cell comprising a chimeric antigen receptor (car) |
CN107141356B (zh) * | 2017-06-07 | 2020-03-13 | 胜武(北京)生物科技有限公司 | 一种光诱导二聚体型嵌合抗原受体 |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
CA3067909A1 (en) | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
US11325957B2 (en) | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
CN107446937B (zh) * | 2017-09-05 | 2020-12-25 | 深圳华云生物技术有限公司 | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 |
JP7382310B2 (ja) * | 2017-09-06 | 2023-11-16 | カリフォルニア インスティチュート オブ テクノロジー | シグナリング及び抗原提示の2機能性レセプター(sabr) |
CN109504697A (zh) * | 2017-09-15 | 2019-03-22 | 上海恒润达生生物科技有限公司 | 一种靶向人源化mesothelin的嵌合抗原受体的方法和用途 |
CA3070861A1 (en) * | 2017-09-22 | 2019-03-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced nfkb signaling |
CN109553686A (zh) * | 2017-09-26 | 2019-04-02 | 南京安吉生物科技有限公司 | 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用 |
GB201715918D0 (en) * | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
US20210363260A1 (en) | 2017-11-13 | 2021-11-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
US20210070831A1 (en) * | 2017-12-14 | 2021-03-11 | Celyad S.A. | Pooling signaling and costimulatory domains in flexible car design |
CN111565737A (zh) * | 2017-12-14 | 2020-08-21 | 蓝鸟生物公司 | Daric白细胞介素受体 |
JP2021506329A (ja) | 2017-12-20 | 2021-02-22 | ザンクト アンナ キンダークレプスフォルシュング | リガンド制御したタンパク質−タンパク質相互作用システム |
EP3502130A1 (en) | 2017-12-20 | 2019-06-26 | St. Anna Kinderkrebsforschung | Ligand regulated protein-protein interaction system |
WO2019126358A1 (en) * | 2017-12-22 | 2019-06-27 | Cell Design Labs, Inc. | Single- and multi-chain chimeric antigen receptors |
BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
WO2019134950A1 (en) | 2018-01-04 | 2019-07-11 | Miltenyi Biotec Gmbh | Chimeric antigen receptor specific for bdca2 antigen |
CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
CN108017717B (zh) * | 2018-01-24 | 2019-08-16 | 首都医科大学宣武医院 | 一种用于体外高效定向扩增的嵌合抗原受体及其应用 |
AU2019218959A1 (en) * | 2018-02-08 | 2020-09-03 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
US20210023170A1 (en) * | 2018-02-12 | 2021-01-28 | University Of Florida Research Foundation, Incorporated | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
JP2021513839A (ja) | 2018-02-16 | 2021-06-03 | カイト ファーマ インコーポレイテッドKite Pharma, Inc | 改変された多能性幹細胞並びに製造方法及び使用方法 |
US11813292B2 (en) * | 2018-03-12 | 2023-11-14 | Immunity Bio, Inc. | Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) |
SG11202008977UA (en) | 2018-03-29 | 2020-10-29 | Fate Therapeutics Inc | Engineered immune effector cells and use thereof |
CA3096200A1 (en) * | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Trans-antigen targeting in heterogeneous cancers and methods of use thereof |
JP2021520788A (ja) | 2018-04-10 | 2021-08-26 | アムジエン・インコーポレーテツド | Dll3に対するキメラ受容体及びその使用方法 |
CN108410908B (zh) * | 2018-04-12 | 2021-08-03 | 吉林大学 | 一种利用植物激素ga及小分子物质pac调节细胞通路的方法 |
EP3774866A1 (en) * | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
JP2021517907A (ja) | 2018-04-18 | 2021-07-29 | アブクロン・インコーポレイテッドAbclon Inc. | スイッチ分子及びスイッチャブルキメラ抗原受容体 |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019210207A2 (en) * | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
CN108715616A (zh) * | 2018-04-27 | 2018-10-30 | 上海恒润达生生物科技有限公司 | 靶向人源化间皮素的嵌合抗原受体方法和用途 |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
US20210214410A1 (en) | 2018-06-01 | 2021-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
CN110577604A (zh) * | 2018-06-07 | 2019-12-17 | 亘喜生物科技(上海)有限公司 | 携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞 |
CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
WO2019246563A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
CN110669138A (zh) * | 2018-07-02 | 2020-01-10 | 中国药科大学 | 一种双嵌合抗原受体、t细胞及其构建方法与应用 |
EP3821012A4 (en) | 2018-07-13 | 2022-04-20 | The Regents of The University of California | RETROTRANSPOSON-BASED DELIVERY VEHICLE AND METHOD OF USE THEREOF |
JOP20210011A1 (ar) | 2018-07-18 | 2021-01-17 | Amgen Inc | مستقبلات خيمرية لـ steap1 وطرق استخدامها |
JP2021533746A (ja) | 2018-08-09 | 2021-12-09 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞およびその組成物を生成するための方法 |
US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
BR112021003305A2 (pt) | 2018-08-31 | 2021-05-25 | Novartis Ag | métodos para produzir células que expressam receptor de antígeno quimérico |
CN112823166A (zh) * | 2018-09-07 | 2021-05-18 | 生物蛋白有限公司 | 用于修饰的t细胞的条件活性嵌合抗原受体 |
EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
EP3632461A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
CN113286608A (zh) * | 2018-10-05 | 2021-08-20 | 圣安娜儿童癌症研究中心 | 嵌合抗原受体(car)组 |
CN113164576A (zh) * | 2018-10-05 | 2021-07-23 | 圣安娜儿童癌症研究中心 | 嵌合抗原受体(car)组 |
EP3632460A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
GB201816839D0 (en) * | 2018-10-16 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Novel control switch |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
EP4198057A1 (en) | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
WO2020118305A1 (en) * | 2018-12-07 | 2020-06-11 | The Trustees Of Columbia University In The City Of New York | Muc4 car-t cells for treating cancer |
BR112021012172A2 (pt) | 2018-12-12 | 2021-08-31 | Kite Pharma, Inc. | Receptores de antígenos quiméricos e de célula t e métodos de uso |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2020141106A1 (en) | 2019-01-03 | 2020-07-09 | Kemijski Institut | Engineered externally regulated artificial transcription regulatory system based on engineered nfat |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020152197A1 (en) | 2019-01-23 | 2020-07-30 | Miltenyi Biotec B.V. & Co. KG | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
EP3930744A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Dll3 targeting chimeric antigen receptors and binding agents |
WO2020180882A1 (en) * | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
EP3946382A1 (en) | 2019-04-04 | 2022-02-09 | UMC Utrecht Holding B.V. | Modified immune receptor constructs |
WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3959305A1 (en) | 2019-04-26 | 2022-03-02 | Allogene Therapeutics, Inc. | Methods of manufacturing allogeneic car t cells |
BR112021021178A2 (pt) | 2019-04-26 | 2022-03-15 | Allogene Therapeutics Inc | Receptores de antígeno quimérico resistentes ao rituximabe e usos destes |
JP2022531577A (ja) | 2019-05-01 | 2022-07-07 | ジュノー セラピューティクス インコーポレイテッド | 改変されたcd247遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法 |
WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
CN113784732B (zh) * | 2019-05-07 | 2024-03-22 | 亘喜生物科技(上海)有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
EP3964238A4 (en) * | 2019-05-07 | 2022-09-14 | Gracell Biotechnologies (Shanghai) Co., Ltd. | MANIPULATED IMMUNE CELL TARGETING BCMA AND USE THEREOF |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
JP2022534921A (ja) | 2019-05-28 | 2022-08-04 | ミルテニイ ビオテック ベー.ファー. ウント コー.カーゲー | 遺伝子改変t細胞の生成方法 |
US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
US20220265715A1 (en) * | 2019-07-24 | 2022-08-25 | Eureka Therapeutics, Inc. | Chimeric antigen receptor t cells and uses thereof |
US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
EP4028049A1 (en) | 2019-09-11 | 2022-07-20 | Miltenyi Biotec B.V. & Co. KG | In vitro method for transduction of t cells in the presence of malignant cells |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US20240122979A1 (en) * | 2019-10-08 | 2024-04-18 | Provincial Health Services Authority | Chimeric Cytokine Receptors |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
WO2021113116A1 (en) * | 2019-12-03 | 2021-06-10 | University Of Massachusetts | Compositions and methods for optogenetic immunotherapy |
CN113087805A (zh) * | 2019-12-31 | 2021-07-09 | 华东师范大学 | 一种共表达免疫调节分子的嵌合抗原受体t细胞的制备及其应用 |
CN115279381A (zh) * | 2020-01-13 | 2022-11-01 | 恩卡尔塔公司 | Bcma定向性细胞免疫疗法组合物和方法 |
EP4093857A4 (en) | 2020-01-23 | 2024-02-21 | Childrens Medical Ct Corp | DIFFERENTIATION OF STROMA-FREE T CELLS FROM HUMAN PLURIPOTENT STEM CELLS |
WO2021156277A1 (en) | 2020-02-04 | 2021-08-12 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
WO2021163618A1 (en) | 2020-02-14 | 2021-08-19 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
JP2023515211A (ja) | 2020-02-27 | 2023-04-12 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
MX2022010604A (es) | 2020-02-27 | 2022-09-09 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
CA3171066A1 (en) * | 2020-03-11 | 2021-09-16 | Saar GILL | Methods and composition for gene delivery using an engineered viral particle |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
KR20230004680A (ko) | 2020-04-17 | 2023-01-06 | 시티 오브 호프 | Flt3-양성 악성 종양의 치료를 위한 flt3-표적화된 키메라 항원 수용체 변형 세포 |
EP3916388A1 (en) | 2020-05-27 | 2021-12-01 | Miltenyi Biotec B.V. & Co. KG | Reagents for detection of chimeric antigen receptor cells |
EP3915578A1 (en) | 2020-05-28 | 2021-12-01 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising c2-set ig-like domains |
MX2022015586A (es) * | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
EP3964585A1 (en) | 2020-09-03 | 2022-03-09 | Miltenyi Biotec B.V. & Co. KG | Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets |
WO2022049217A1 (en) | 2020-09-04 | 2022-03-10 | Miltenyi Biotec B.V. & Co. KG | System for inducible expression of an adapter in immune cells |
WO2022096664A1 (en) | 2020-11-09 | 2022-05-12 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
MX2023005609A (es) | 2020-11-13 | 2023-05-29 | Novartis Ag | Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car). |
AU2021409801A1 (en) | 2020-12-21 | 2023-06-22 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
EP4284822A1 (en) * | 2021-01-29 | 2023-12-06 | Outpace Bio, Inc. | Small molecule-regulated cell signaling expression system |
US20240115608A1 (en) * | 2021-02-10 | 2024-04-11 | The Regents Of The University Of California | Immune receptors with synthetic co-stimulatory domains |
GB202104030D0 (en) * | 2021-03-23 | 2021-05-05 | Autolus Ltd | Signalling system |
WO2022212858A2 (en) * | 2021-04-01 | 2022-10-06 | A2 Biotherapeutics, Inc. | Polypeptides targeting hla-a*11 and methods of use thereof |
GB202108366D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
WO2023009989A1 (en) | 2021-07-26 | 2023-02-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
WO2023044304A1 (en) * | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
WO2023062113A1 (en) | 2021-10-15 | 2023-04-20 | Miltenyi Biotec B.V. & Co. KG | Method for the generation of genetically modified nk cells |
WO2023130462A1 (zh) * | 2022-01-10 | 2023-07-13 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
CN114736306B (zh) * | 2022-03-01 | 2024-04-19 | 中国科学院深圳先进技术研究院 | 一种受化学调控的蛋白酶工具及其配套底物 |
WO2023187031A1 (en) | 2022-04-01 | 2023-10-05 | Miltenyi Biotec B.V. & Co. KG | A system for drug-inducible expression of a polynucleotide |
WO2023217796A1 (en) | 2022-05-10 | 2023-11-16 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
WO2023220459A1 (en) * | 2022-05-13 | 2023-11-16 | Northwestern University | Active loading of cargo entity into lipid bilayer particles using dimerization domains |
WO2023222617A1 (en) | 2022-05-16 | 2023-11-23 | Miltenyi Biotec B.V. & Co. KG | Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof |
WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
EP4342488A1 (en) | 2022-09-26 | 2024-03-27 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor specific for folate receptor 1 |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024078995A1 (en) | 2022-10-15 | 2024-04-18 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
CA2052928A1 (en) * | 1990-10-15 | 1992-04-16 | John J. Siekierka | Genes encoding the human fk-506 binding protein and a.s. cerevisiae homolog, fkb1 and their expression |
EP0517895B1 (en) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
TW197439B (es) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
AU3140093A (en) | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
AU4242993A (en) | 1992-05-21 | 1993-12-13 | Penn State Research Foundation, The | Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
CA2155728C (en) | 1993-02-12 | 2000-04-25 | Gerald R. Crabtree | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
CA2166118C (en) | 1993-06-24 | 2007-04-17 | Frank L. Graham | Adenovirus vectors for gene therapy |
US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US6150527A (en) | 1994-08-18 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Synthetic multimerizing agents |
US6133456A (en) | 1994-08-18 | 2000-10-17 | Ariad Gene Therapeutics, Inc. | Synthetic multimerizing agents |
NZ511170A (en) | 1994-12-09 | 2005-02-25 | Imp College Innovations Ltd | Administering anitgens for protection against Salmonella infections |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
WO1998058927A1 (en) | 1997-06-20 | 1998-12-30 | Baker Norton Pharmaceuticals, Inc. | Soluble prodrugs of paclitaxel |
US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
CA2305399A1 (en) | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Taxoid derivatives and process for producing the same |
JP2002508971A (ja) | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
ATE264863T1 (de) | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
GB9925854D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
US6916846B2 (en) | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
GB0105402D0 (en) | 2001-03-05 | 2001-04-18 | Inpharmatica Ltd | Novel proteins |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
WO2003078575A2 (en) | 2002-03-11 | 2003-09-25 | The Johns Hopkins University | Molecular switches and methods for making and using the same |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US7404950B2 (en) | 2003-02-18 | 2008-07-29 | Baylor College Of Medicine | Induced activation in dendritic cell |
US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
US8236925B1 (en) | 2005-08-26 | 2012-08-07 | University Of Minnesota | Protein nanorings |
AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
WO2011053825A2 (en) * | 2009-10-30 | 2011-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment or prevention of mitochondrial diseases |
EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
WO2011119773A1 (en) * | 2010-03-23 | 2011-09-29 | Roeth Jeremiah F | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
US8802438B2 (en) | 2010-04-16 | 2014-08-12 | Children's Medical Center Corporation | Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
CN103201293B (zh) | 2010-09-08 | 2016-04-27 | 哈洛齐梅公司 | 评估和鉴定或发展条件活性治疗蛋白的方法 |
FR2968013A1 (fr) * | 2010-11-29 | 2012-06-01 | Cis Bio Int | Methode de retention conditionnelle d'une proteine d'interet dans le reticulum endoplasmique |
PT3214091T (pt) | 2010-12-09 | 2019-01-11 | Univ Pennsylvania | Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro |
KR20140004174A (ko) * | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
EP3279315A3 (en) | 2012-05-25 | 2018-02-28 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
JP6352920B2 (ja) | 2012-09-04 | 2018-07-04 | セレクティス | 多重鎖キメラ抗原受容体およびその使用 |
WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
CN110423282B (zh) | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
SG11201506974XA (en) | 2013-03-14 | 2015-10-29 | Bellicum Pharmaceuticals Inc | Methods for controlling t cell proliferation |
WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2015057852A1 (en) * | 2013-10-15 | 2015-04-23 | The California Institute For Biomedical Research | Chimeric antigen receptor t cell switches and uses thereof |
EP3087101A4 (en) | 2013-12-20 | 2017-12-06 | Novartis AG | Regulatable chimeric antigen receptor |
CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
EP3811970A1 (en) * | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
EP3204491A1 (en) | 2014-10-07 | 2017-08-16 | Cellectis | Method for modulating car-induced immune cells activity |
EP3377523A4 (en) | 2015-11-19 | 2019-06-19 | The Regents of The University of California | IMMUNITY CELL RECEIVERS REPRESSIBLE UNDER CONDITIONS AND METHODS OF USING THE SAME |
KR20180096788A (ko) | 2016-01-08 | 2018-08-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 조건적 활성 이종이량체 폴리펩티드 및 이의 사용 방법 |
-
2014
- 2014-02-14 CN CN201910722248.1A patent/CN110423282B/zh active Active
- 2014-02-14 CN CN201480016737.0A patent/CN105142677B/zh active Active
- 2014-02-14 EP EP21158396.8A patent/EP3881868B1/en active Active
- 2014-02-14 ES ES19188398T patent/ES2868247T3/es active Active
- 2014-02-14 KR KR1020197034038A patent/KR102132246B1/ko active Application Filing
- 2014-02-14 BR BR112015019640-3A patent/BR112015019640A2/pt active IP Right Grant
- 2014-02-14 EP EP17187293.0A patent/EP3300745B9/en active Active
- 2014-02-14 PT PT191883982T patent/PT3613439T/pt unknown
- 2014-02-14 IL IL305629A patent/IL305629A/en unknown
- 2014-02-14 SI SI201431421T patent/SI3300745T1/sl unknown
- 2014-02-14 EP EP14751227.1A patent/EP2956175B1/en active Active
- 2014-02-14 WO PCT/US2014/016527 patent/WO2014127261A1/en active Application Filing
- 2014-02-14 KR KR1020237003986A patent/KR20230022452A/ko not_active Application Discontinuation
- 2014-02-14 PT PT147512271T patent/PT2956175T/pt unknown
- 2014-02-14 KR KR1020217038402A patent/KR20210147101A/ko not_active Application Discontinuation
- 2014-02-14 KR KR1020207019131A patent/KR102332790B1/ko active IP Right Grant
- 2014-02-14 MX MX2015010522A patent/MX369545B/es active IP Right Grant
- 2014-02-14 EP EP23198143.2A patent/EP4303232A3/en active Pending
- 2014-02-14 JP JP2015558159A patent/JP6450690B2/ja active Active
- 2014-02-14 HU HUE14751227A patent/HUE036250T2/hu unknown
- 2014-02-14 AU AU2014216130A patent/AU2014216130B2/en active Active
- 2014-02-14 PL PL17187293T patent/PL3300745T3/pl unknown
- 2014-02-14 CA CA2901115A patent/CA2901115A1/en active Pending
- 2014-02-14 EP EP19188398.2A patent/EP3613439B1/en active Active
- 2014-02-14 DK DK17187293T patent/DK3300745T3/da active
- 2014-02-14 PL PL19188398T patent/PL3613439T3/pl unknown
- 2014-02-14 ES ES17187293T patent/ES2758227T3/es active Active
- 2014-02-14 KR KR1020157024731A patent/KR102064230B1/ko active IP Right Grant
- 2014-02-14 PL PL14751227T patent/PL2956175T3/pl unknown
- 2014-02-14 IL IL272279A patent/IL272279B2/en unknown
- 2014-02-14 LT LTEP14751227.1T patent/LT2956175T/lt unknown
- 2014-02-14 HU HUE17187293A patent/HUE047487T2/hu unknown
- 2014-02-14 ES ES14751227T patent/ES2653487T3/es active Active
- 2014-02-14 LT LT17187293T patent/LT3300745T/lt unknown
- 2014-02-14 DK DK14751227.1T patent/DK2956175T3/da active
- 2014-02-14 PT PT171872930T patent/PT3300745T/pt unknown
- 2014-02-14 US US14/766,105 patent/US20150368342A1/en not_active Abandoned
- 2014-02-14 SI SI201431844T patent/SI3613439T1/sl unknown
-
2015
- 2015-04-01 NO NO15162181A patent/NO2929995T3/no unknown
- 2015-08-10 IL IL240472A patent/IL240472B/en active IP Right Grant
- 2015-08-14 MX MX2019013498A patent/MX2019013498A/es unknown
-
2016
- 2016-03-09 US US15/064,938 patent/US9587020B2/en active Active
- 2016-06-08 HK HK16106629.8A patent/HK1218625A1/zh unknown
-
2017
- 2017-01-30 US US15/419,729 patent/US9821012B2/en active Active
- 2017-08-04 US US15/669,707 patent/US10632152B2/en active Active
- 2017-11-01 US US15/801,133 patent/US10105391B2/en active Active
- 2017-12-07 US US15/835,329 patent/US10888581B2/en active Active
-
2018
- 2018-02-15 AU AU2018201102A patent/AU2018201102A1/en not_active Abandoned
- 2018-10-04 HK HK18112705.1A patent/HK1253407A1/zh unknown
- 2018-12-10 JP JP2018230498A patent/JP6687712B2/ja active Active
-
2019
- 2019-10-08 AU AU2019246785A patent/AU2019246785B2/en active Active
- 2019-11-26 HR HRP20192123TT patent/HRP20192123T1/hr unknown
- 2019-11-27 CY CY20191101245T patent/CY1122386T1/el unknown
-
2020
- 2020-03-19 US US16/824,434 patent/US11478510B2/en active Active
- 2020-04-02 JP JP2020066759A patent/JP7014843B2/ja active Active
- 2020-12-08 US US17/115,565 patent/US20210196757A1/en active Pending
-
2021
- 2021-06-17 AU AU2021204054A patent/AU2021204054B2/en active Active
-
2022
- 2022-01-20 JP JP2022006902A patent/JP7317159B2/ja active Active
- 2022-09-14 US US17/932,259 patent/US20230051989A1/en active Pending
-
2023
- 2023-07-12 AU AU2023204612A patent/AU2023204612A1/en active Pending
- 2023-07-18 JP JP2023116579A patent/JP2023145542A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2653487T3 (es) | Receptor de antígeno quimérico y métodos de uso del mismo | |
CL2015002654A1 (es) | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso | |
DOP2018000213A (es) | Receptores de antígenos quiméricos y células t y métodos de uso | |
CL2019002036A1 (es) | Anticuerpo contra bcma y su uso. | |
CO2019000946A2 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
MX2018005618A (es) | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. | |
CL2018001172A1 (es) | Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer | |
DOP2018000159A (es) | Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip | |
MX2018000278A (es) | Terapia de receptores quimericos de puntos de control inmunitarios. | |
CL2017000438A1 (es) | Sistema de señalización | |
CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
CL2015002788A1 (es) | Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario con el uso de un dispositivo móvil del usuario | |
PH12017500042A1 (en) | Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
MY195115A (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
PE20210648A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
ECSP14030789A (es) | Anticuerpos Anti-FcRn | |
EA201501063A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
NI201300051A (es) | Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer. | |
CL2017002881A1 (es) | Anticuerpos anti-fcrn | |
MX2016008196A (es) | Anticuerpos y metodos de uso. | |
AR095891A1 (es) | Formulaciones adhesivas extruibles que contienen copolímeros en bloque olefínicos | |
UY35835A (es) | Anticuerpos específicos para FcRn. | |
UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ |